AbbVie Inc (ABBV)vsP3 Health Partners Inc (PIII)
ABBV
AbbVie Inc
$247.87
+0.78%
HEALTHCARE · Cap: $430.82B
PIII
P3 Health Partners Inc
$11.58
+6.34%
HEALTHCARE · Cap: $2.14B
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 4273% more annual revenue ($64.39B vs $1.47B). ABBV leads profitability with a 9.8% profit margin vs -8.6%. ABBV earns a higher WallStSmart Score of 73/100 (B).
ABBV
Strong Buy73
out of 100
Grade: B
PIII
Avoid34
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-63.1%
Fair Value
$150.90
Current Price
$247.87
$96.97 premium
Intrinsic value data unavailable for PIII.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Growing faster than its price suggests
Every $100 of equity generates 62 in profit
Strong operational efficiency at 39.6%
Earnings expanding 290.4% YoY
Conservative balance sheet, low leverage
Conservative balance sheet, low leverage
Areas to Watch
Premium valuation, high expectations priced in
Distress zone — elevated risk
3.5% revenue growth
0.0% earnings growth
Operating margin of 2.1%
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, PEG Ratio, Return on Equity. Revenue growth of 10.2% demonstrates continued momentum. PEG of 0.41 suggests the stock is reasonably priced for its growth.
Bull Case : PIII
The strongest argument for PIII centers on Debt/Equity.
Bear Case : ABBV
The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 68.9x leaves little room for execution misses.
Bear Case : PIII
The primary concerns for PIII are Revenue Growth, EPS Growth, Operating Margin.
Key Dynamics to Monitor
ABBV profiles as a value stock while PIII is a turnaround play — different risk/reward profiles.
PIII carries more volatility with a beta of 1.62 — expect wider price swings.
ABBV is growing revenue faster at 10.2% — sustainability is the question.
ABBV generates stronger free cash flow (3.6B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (73/100 vs 34/100) and 10.2% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
P3 Health Partners Inc
HEALTHCARE · MEDICAL CARE FACILITIES · USA
P3 Health Partners Inc (PIII) is a forward-thinking healthcare organization dedicated to enhancing care quality and minimizing costs through innovative, data-driven methodologies. Specializing in value-based care models, the company leverages telehealth technologies and advanced analytics to deliver tailored healthcare solutions, particularly targeting underserved populations. By collaborating with community organizations and maintaining a robust network of primary care providers and specialists, PIII addresses the growing demand for efficient healthcare services. With a steadfast commitment to high-quality, cost-effective care, PIII is well-positioned to thrive in the evolving healthcare environment.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?